Comparative Proteomic Analysis of Intra- and Interindividual Variation in Human Cerebrospinal Fluid*S

Cerebrospinal fluid (CSF) is a potential source of biomarkers for many disorders of the central nervous system, including Alzheimer disease (AD). Prior to comparing CSF samples between individuals to identify patterns of disease-associated proteins, it is important to examine variation within individuals over a short period of time so that one can better interpret potential changes in CSF between individuals as well as changes within a given individual over a longer time span. In this study, we analyzed 12 CSF samples, composed of pairs of samples from six individuals, obtained 2 weeks apart. Multiaffinity depletion, two-dimensional DIGE, and tandem mass spectrometry were used. A number of proteins whose abundance varied between the two time points was identified for each individual. Some of these proteins were commonly identified in multiple individuals. More importantly, despite the intraindividual variations, hierarchical clustering and multidimensional scaling analysis of the proteomic profiles revealed that two CSF samples from the same individual cluster the closest together and that the between-subject variability is much larger than the within-subject variability. Among the six subjects, comparison between the four cognitively normal and the two very mildly demented subjects also yielded some proteins that have been identified in previous AD biomarker studies. These results validate our method of identifying differences in proteomic profiles of CSF samples and have important implications for the design of CSF biomarker studies for AD and other central nervous system disorders.

[1]  Julie Perkins,et al.  Proteomic analysis of human serum by two-dimensional differential gel electrophoresis after depletion of high-abundant proteins. , 2004, Journal of proteome research.

[2]  Christian A. Rees,et al.  Systematic variation in gene expression patterns in human cancer cell lines , 2000, Nature Genetics.

[3]  Trey Sunderland,et al.  Decreased beta-amyloid1-42 and increased tau levels in cerebrospinal fluid of patients with Alzheimer disease. , 2003, JAMA.

[4]  S. Gygi,et al.  Quantitative analysis of complex protein mixtures using isotope-coded affinity tags , 1999, Nature Biotechnology.

[5]  J. Trojanowski,et al.  Increased 8,12‐iso‐iPF2α‐VI in Alzheimer's disease: Correlation of a noninvasive index of lipid peroxidation with disease severity , 2000, Annals of neurology.

[6]  J. Morris,et al.  Pathologic correlates of nondemented aging, mild cognitive impairment, and early-stage alzheimer’s disease , 2001, Journal of Molecular Neuroscience.

[7]  M. Takigawa,et al.  Recognition of YKL-39, a human cartilage related protein, as a target antigen in patients with rheumatoid arthritis , 2001, Annals of the rheumatic diseases.

[8]  K. Blennow,et al.  A population-based study of tau protein and ubiquitin in cerebrospinal fluid in 85-year-olds: relation to severity of dementia and cerebral atrophy, but not to the apolipoprotein E4 allele. , 1995, Neurodegeneration : a journal for neurodegenerative disorders, neuroprotection, and neuroregeneration.

[9]  L. Liotta,et al.  CSF proteome: a protein repository for potential biomarker identification , 2005, Expert review of proteomics.

[10]  R. Aebersold,et al.  Quantitative profiling of differentiation-induced microsomal proteins using isotope-coded affinity tags and mass spectrometry , 2001, Nature Biotechnology.

[11]  Mu Wang,et al.  The impact of blood contamination on the proteome of cerebrospinal fluid , 2005, Proteomics.

[12]  R. Aitken,et al.  Identification of post‐translational modifications that occur during sperm maturation using difference in two‐dimensional gel electrophoresis , 2005, Proteomics.

[13]  R. Narayanan,et al.  Cancer gene discovery using digital differential display. , 2000, Cancer research.

[14]  J. Price,et al.  Clinicopathologic studies in cognitively healthy aging and Alzheimer's disease: relation of histologic markers to dementia severity, age, sex, and apolipoprotein E genotype. , 1998, Archives of neurology.

[15]  J. Morris,et al.  Clinical Dementia Rating: A Reliable and Valid Diagnostic and Staging Measure for Dementia of the Alzheimer Type , 1997, International Psychogeriatrics.

[16]  D. Hochstrasser,et al.  A panel of cerebrospinal fluid potential biomarkers for the diagnosis of Alzheimer's disease , 2003, Proteomics.

[17]  R. Caprioli,et al.  Proteome analysis of human colon cancer by two‐dimensional difference gel electrophoresis and mass spectrometry , 2004, Proteomics.

[18]  C. Rohlff.  Proteomics in molecular medicine: Applications in central nervous systems disorders , 2000, Electrophoresis.

[19]  W. Markesbery,et al.  Decreased thioredoxin and increased thioredoxin reductase levels in Alzheimer's disease brain. , 2000, Free radical biology & medicine.

[20]  W. Klunk,et al.  Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound‐B , 2004, Annals of neurology.

[21]  Kelvin H. Lee,et al.  Studies of potential cerebrospinal fluid molecular markers for Alzheimer's disease , 2002, Electrophoresis.

[22]  G. Siest,et al.  Apolipoprotein E, transthyretin and actin in the CSF of Alzheimer's patients: relation with the senile plaques and cytoskeleton biochemistry , 1998, FEBS letters.

[23]  Benoit Mulsant,et al.  Detection and Management of Cognitive Impairment in Primary Care: The Steel Valley Seniors Survey , 2004, Journal of the American Geriatrics Society.

[24]  K. Blennow,et al.  Ubiquitin in Cerebrospinal Fluid in Alzheimer's Disease and Vascular Dementia , 1994, International Psychogeriatrics.

[25]  D. Christmann,et al.  Cerebrospinal fluid transthyretin: aging and late onset Alzheimer’s disease , 1997, Journal of neurology, neurosurgery, and psychiatry.

[26]  H. Riisøen.  Reduced prealbumin (transthyretin) in CSF of severely demented patients with Alzheimer's disease , 1988, Acta neurologica Scandinavica.

[27]  D. Bennett,et al.  Vitamin E and donepezil for the treatment of mild cognitive impairment. , 2005, The New England journal of medicine.

[28]  K. Blennow,et al.  A new procedure for detecting brain-specific proteins in cerebrospinal fluid , 2005, Journal of neural transmission.

[29]  Matthew Davison,et al.  Validation and development of fluorescence two‐dimensional differential gel electrophoresis proteomics technology , 2001, Proteomics.

[30]  Jing Zhang,et al.  Quantitative proteomics of cerebrospinal fluid from patients with Alzheimer disease. , 2005, Journal of Alzheimer's disease : JAD.

[31]  C. Carella,et al.  Increased cerebrospinal fluid levels of 3,3',5'-triiodothyronine in patients with Alzheimer's disease. , 2005, The Journal of clinical endocrinology and metabolism.

[32]  D. Mash,et al.  Neuropathological and neuropsychological changes in "normal" aging: evidence for preclinical Alzheimer disease in cognitively normal individuals. , 1998, Journal of neuropathology and experimental neurology.

[33]  Stephen Russell,et al.  High‐throughput proteomic analysis of human infiltrating ductal carcinoma of the breast , 2003, Proteomics.

[34]  T. Montine,et al.  Cerebrospinal fluid F2‐isoprostane levels are increased in Alzheimer's disease , 1998, Annals of neurology.

[35]  P. Liberski,et al.  Amyloid-beta and tau proteins as biochemical markers of Alzheimer's disease. , 2004, Acta neurobiologiae experimentalis.

[36]  Kaj Blennow,et al.  Proteomic studies of potential cerebrospinal fluid protein markers for Alzheimer's disease. , 2003, Brain research. Molecular brain research.

[37]  I. Grundke‐Iqbal,et al.  Elevated Levels of τ and Ubiquitin in Brain and Cerebrospinal Fluid in Alzheimer's Disease , 1997, International Psychogeriatrics.

[38]  D. Baunsgaard,et al.  Mechanisms of hydrazine toxicity in rat liver investigated by proteomics and multivariate data analysis , 2004, Proteomics.

[39]  Ting Wang,et al.  RNA interference of achaete-scute homolog 1 in mouse prostate neuroendocrine cells reveals its gene targets and DNA binding sites. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[40]  C. Lake,et al.  Daily Fluctuations in Catecholamines, Monoamine Metabolites, Cyclic AMP, and , 1980 .

[41]  I. Pollack,et al.  Proteomic characterization of harvested pseudopodia with differential gel electrophoresis and specific antibodies , 2005, Laboratory Investigation.

[42]  R. Tanzi,et al.  Twenty Years of the Alzheimer’s Disease Amyloid Hypothesis: A Genetic Perspective , 2005, Cell.

[43]  Xianlin Han,et al.  Cerebrospinal fluid sulfatide is decreased in subjects with incipient dementia , 2003, Annals of neurology.

[44]  A. Shevchenko,et al.  Fast-response proteomics by accelerated in-gel digestion of proteins. , 2003, Analytical chemistry.

[45]  T. Kudo,et al.  Alzheimer disease: correlation of cerebro-spinal fluid and brain ubiquitin levels , 1994, Brain Research.

[46]  Tadashi Kondo,et al.  Proteomic signature of human cancer cells , 2004, Proteomics.

[47]  K. Parker,et al.  Multiplexed Protein Quantitation in Saccharomyces cerevisiae Using Amine-reactive Isobaric Tagging Reagents*S , 2004, Molecular & Cellular Proteomics.

[48]  Jennifer M. Campbell,et al.  The characteristics of peptide collision-induced dissociation using a high-performance MALDI-TOF/TOF tandem mass spectrometer. , 2000, Analytical chemistry.

[49]  E. Thompson.  The CSF proteins: A biochemical approach , 1988 .

[50]  Brian,et al.  Human cartilage gp-39, a major secretory product of articular chondrocytes and synovial cells, is a mammalian member of a chitinase protein family. , 1993, The Journal of biological chemistry.

[51]  B. Sitek,et al.  Identification of Dynamic Proteome Changes Upon Ligand Activation of Trk-Receptors Using Two-dimensional Fluorescence Difference Gel Electrophoresis and Mass Spectrometry* , 2005, Molecular & Cellular Proteomics.

[52]  S. Gaskell,et al.  Comparative proteomics of primitive hematopoietic cell populations reveals differences in expression of proteins regulating motility. , 2004, Blood.

[53]  Stephen O. David,et al.  A novel experimental design for comparative two‐dimensional gel analysis: Two‐dimensional difference gel electrophoresis incorporating a pooled internal standard , 2003, Proteomics.

[54]  Kaj Blennow,et al.  Proteome analysis of cerebrospinal fluid proteins in Alzheimer patients , 2002, Neuroreport.